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Current strategies for the production of therapeutic mAbs include
the use of mammalian cell systems to recombinantly produce Abs
derived from mice bearing human Ig transgenes, humanization of
rodent Abs, or phage libraries. Generation of hybridomas secreting
human mAbs has been previously reported; however, this ap-
proach has not been fully exploited for immunotherapy develop-
ment. We previously reported the use of transient regulation of
cellular DNA mismatch repair processes to enhance traits (e.g.,
affinity and titers) of mAb-producing cell lines, including hybrid-
omas. We reasoned that this process, named morphogenics, could
be used to improve suboptimal hybridoma cells generated by
means of ex vivo immunization and immortalization of antigen-
specific human B cells for therapeutic Ab development. Here we
present a platform process that combines hybridoma and morpho-
genics technologies for the generation of fully human mAbs
specific for disease-associated human antigens. We were able to
generate hybridoma lines secreting mAbs with high binding spec-
ificity and biological activity. One mAb with strong neutralizing
activity against human granulocyte–macrophage colony-stimulat-
ing factor was identified that is now considered for preclinical
development for autoimmune disease indications. Moreover,
these hybridoma cells have proven suitable for genetic optimiza-
tion using the morphogenics process and have shown potential for
large-scale manufacturing.
morphogenics  therapeutic antibody
Several disease-associated antigens are currently being tar-geted using therapeutic mAbs because of their unique phar-
macological and safety profiles. Current strategies for the pro-
duction of therapeutic mAbs include the use of mammalian cell
systems (i.e., CHO or NS0 transfectomas) to recombinantly
produce mAbs derived from immunization of transgenic mice
bearing human Ig genes (xenomice), humanization of rodent
mAbs, or through screening of human mAb phage libraries (1).
Early development efforts used rodent systems to generate
mAbs; however, high immunogenicity prevented their use in
indications where prolonged dosing in humans was required.
Therapeutic mAbs have more recently evolved into chimeric
(rodent variable and human constant regions), humanized (hu-
man sequence except for rodent complementarity-determining
regions), and fully human Abs to minimize allergic response.
Another strategy entails introducing amino acid changes in the
Ab sequence to mask rodent epitopes. In some applications, an
important aspect of a therapeutic mAb is its ability to elicit
immune effector functions, such as Ab-dependent cellular cy-
totoxicity. Rodent mAbs have been shown to poorly mediate
effector functions in humans because of sequence differences in
the Fc region; therefore, chimerization or humanization is
required to gain optimal pharmacological properties. In addi-
tion, mAbs with fully human sequences may still fail to support
Ab-dependent cellular cytotoxicity if they are produced in
non-human host cells that may alter native glycosylation pattern
of mAbs (2).
In view of these facts, an ideal scenario is one where thera-
peutic Abs are produced by human B cells. In this case, mAbs
would be able to exert human effector functions and have very
limited immunogenicity because of their native human structure.
The generation of hybridoma or Epstein–Barr virus-transformed
lymphoblastoid lines derived from human B cells has been
previously reported (3–5); however, there is limited information
on the characterization of these Abs and the lines with respect
to their long-term stability, suitability to manufacturing pro-
cesses, and the Ab’s pharmacological properties (1).
In this report we present a process employing primary human
B cells for generating cell lines producing human mAbs. Human
B cells are immunized ex vivo in the presence of human antigens
and then immortalized by means of cell fusion. Alternatively,
selected donors are identified whose sera have high immunore-
activity to antigens of interest. Hybrid cells derived from these
individuals’ B cells are screened for secretion of antigen-specific
mAbs. As a result of this effort, we generated mAbs specific to
a number of human antigens, including human mesothelin and
granulocyte–macrophage colony-stimulating factor (GM-CSF).
One mAb showed strong neutralizing activity against human
GM-CSF and is now considered for preclinical development for
autoimmune disease indications. In addition, we show that
hybridoma lines producing these mAbs are suitable for genetic
optimization using the morphogenics whole-genome evolution
method that we recently described, which is able to improve
qualities associated with Ig titers and affinity (6, 19).
Results
Generation of Antigen-Specific HumanmAbs.Ex vivo immunizations
were carried out by using cryopreserved B cells obtained from
volunteer subjects (healthy donors) as described inMaterials and
Methods. Alternatively, B cells were obtained from human
subjects whose sera contained high titers of mAbs specific to an
antigen of interest. The rationale of the latter approach stems
from the possibility that some antigen-specific mAbs could result
from an abnormal immune response (as in the case of autoim-
mune patients) or derive from an in vivo immune response to
tumor, microbial, or vaccine antigens. In this study we obtained
lymphocytes from patients affected by pulmonary alveolar pro-
teinosis, a rare lung disorder of unknown etiology characterized
by alveolar filling with floccular material. These patients have
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been shown to exhibit high titers of mAbs to human GM-CSF
(7). GM-CSF has been identified as a potential factor in the
abnormal inflammatory response associated with rheumatoid
arthritis as well as other autoimmune diseases (8–10). Therefore,
we sought to generate human mAbs against this cytokine that
could be applied for prospective immunotherapy. Several anti-
gen-reacting human mAbs were identified after fusion of ex vivo
immunized cells and from hybridoma libraries generated from
pulmonary alveolar proteinosis patients’ B cells. Four hybridoma
lines, E5 (IgM), G7 (IgM), E10 (IgG), and G9 (IgG), were
selected for further studies, and the human mAbs they produce
were tested for specificity by ELISA. Fig. 1 shows that E5, G7,
and E10 human mAbs reacted only with human GM-CSF and
none of the other 10 unrelated antigens tested, including murine
GM-CSF, which shares a 53% identity with the human homolog.
Similar results were obtained for the G9 hybridoma (data not
shown). FACS analyses were carried out to confirm specificity of
these human mAbs. Human GM-CSF was allowed to bind to the
surface of mouse hybridoma cells, which express membrane-
bound mAbs specific to human GM-CSF at a different epitope
(data not shown). E5 mAb bound the surface of these cells under
these conditions, as indicated by the fluorescence intensity shift
(Fig. 2A Bottom). This result demonstrates the ability of E5 mAb
to bind native human GM-CSF. In absence of cell-bound GM-
CSF, E5 mAb did not crossreact with any of the membrane-
bound proteins expressed by these hybridoma cells (Fig. 2A
Middle). Similarly, E10 mAb showed high specificity by FACS
analysis (data not shown). In addition, because E10 mAb was
found associated to the hybridoma cell membrane, we were able
to show its ability to bind soluble, phycoerythrin (PE)-labeled
GM-CSF by FACS (Fig. 2B Middle). Binding specificity was
demonstrated by preincubation of the E10 hybridoma cells with
an excess of unlabeled GM-CSF (Fig. 2B Bottom).
Human mesothelin is a glycosylphosphatidyl inositol-
anchored surface protein expressed in mesothelioma, ovarian,
and pancreatic cancer tissues (11, 12). Although its biological
role is still unclear, mesothelin has been proposed as a potential
target for cell vaccine- and mAb-based therapies of both pan-
creatic and mesothelioma cancers because of its tumor-restricted
expression pattern (13, 14). We sought to develop fully human
mAbs against this target by means of ex vivo immunization of
human B cells. Although several mesothelin-reacting hybrid-
omas were identified after screening, the hybridoma C12 (IgM)
was selected for additional testing because of its robust speci-
ficity profile (data not shown). This mAb showed strong surface
staining of mesothelin-expressing cells but not mesothelin-
negative cells (Fig. 3A). No surface staining was observed when
normal human Ig from serum was used (Fig. 3B).
De Novo Class Switch of Human mAbs. Using the two strategies
described above, we were able to generate both IgG and IgM
Fig. 1. Antigen panel ELISA for selection of antigen-specific human mAbs.
Three GM-CSF-specific human mAbs, E10, G7, and E5, reacted with human
GM-CSF and none of the other antigens in the panel. 215, murine mAb specific
to human GM-CSF (hGM-CSF); mGM-CSF, murine GM-CSF.
Fig. 2. Human mAbs highly specific to native human GM-CSF. (A) Murine
hybridoma cells presenting cell surface Ig to human GM-CSF were loaded with
(Bottom) or without (Top and Middle) soluble human GM-CSF. mAb E5 was
subsequently added (Middle and Bottom) to the reaction, and its binding to
human GM-CSF was measured by using FITC-conjugated goat anti-human Ig.
E5 did not bind any of the surface proteins expressed by the murine hybridoma
cells (Middle) but bound only soluble GM-CSF captured by the cell surface Ig
(Bottom). (B) PE-labeled human GM-CSF (PE-GM) can react to Ig expressed on
E10 cell surface (Middle). Excess of unlabeled GM-CSF competed for PE-GM
binding (Bottom). No PE-GM binding was seen in absence of both PE-GM and
GM-CSF (Top).
Fig. 3. Human mAb highly specific to human mesothelin tumor antigen. (A)
mAb C12 (10 gml) was reacted to mesothelin-negative () or positive ()
cells followed by FITC-conjugated goat anti-human Ig. Bound Ig causing
shifting of fluorescence intensity was detected only with cells expressing
mesothelin. (B) Normal human IgM was reacted to same cells as in A. No
fluorescence shift was observed with either cell type, demonstrating specific-
ity of this assay.
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humanmAbs to a variety of human and non-human antigens. On
average, one-third of antigen-reacting Abs generated by using
the procedure described above are of IgG isotype. Although
most of therapeutic Abs in the market are of the IgG isotype,
cancer trials testing potentially therapeutic IgM mAbs have
shown regression of tumors in vivo (15, 16). These clinical
responses can be attributable to the ability of IgM to strongly fix
and activate the complement pathway and effectively kill tumor
cells. IgG binds to the Fc receptors on macrophages and natural
killer cells and thus can mediate Ab-dependent cellular cyto-
toxicity activity against tumor cells. Ideally, both IgG and IgM
with identical specificity (same antigen and epitope) should be
tested for best pharmacological activity in vivo. In the case where
an IgG isotype is preferred, we followed a quick robust proce-
dure (see Materials and Methods) for de novo class-switching of
IgM. Using the E5 line as an example, we could readily identify
a rare subset of cells that had class-switched to an IgG isotype
under the growth conditions used. The E5 IgG showed identical
nucleotide sequence in its variable region (data not shown) and
reactivity to GM-CSF (Fig. 4) similar to that of the parental E5
IgM. The antimesothelin C12 hybridoma cells were also class-
switched to an IgG-secreting hybridoma (data not shown),
demonstrating reproducibility of this method.
Biological Activities of Human mAbs. Pharmacological properties
sought for therapeutic mAbs that target soluble mediators of
disease include the ability to neutralize growth factors. As
mentioned above, one such example is GM-CSF as a mediator
of rheumatoid arthritis (8–10). We assessed the ability of our
human mAbs to block GM-CSF function using a cell-based assay
whereby the growth of human erythroblastoid cells (TF1) de-
pends on the presence of this cytokine in their culture medium.
As shown in Fig. 5, both E10 and G9 significantly inhibited
GM-CSF-dependent cell growth, whereas the human IgG iso-
type control showed no effect. The difference in potency seen
between E10 and G9 correlates well with their apparent affin-
ities of 870 and 14 picomolar, respectively. The E5 mAb showed
only minimal neutralizing activity (data not shown), consistent
with its lower affinity (5 nM).
Assessment of Titers and Stability of Hybridomas Secreting Human
mAbs. An important property of a mAb-manufacturing line is
stability of Ig secretion during the entire batch manufacturing
cycle. In one scenario, where the cycle duration is 2 months, a
line doubling every 24 h would go through60 generations from
thawing to harvest. We used E5 line as a model for testing mAb
titers and production stability of hybridoma generated using our
method. A clone derived from this line, 3D2, showed a doubling
time of 24 h and was recloned by limiting dilutions after 2
months of continuous culturing. The frequency of producing
clones was determined by means of ELISA, measuring Ig
concentrations in their conditioned media normalized for cell
densities. Fig. 6A shows that all E5-3D2 subclones tested secrete
high levels of Ig, demonstrating homogeneous retention of Ig
production in this cell population after 60 generations. Ig
production was then assessed by using a small-scale (15 ml)
hollow-fiber system. Cells were inoculated in a hollow-fiber
cartridge and continuously fed by using an inline reservoir
containing 1 liter of fresh medium. Starting on day 5, all
conditioned medium from the cartridge (15 ml) was harvested
daily and replaced with fresh medium. Fermentation was carried
out for additional 4 days, and daily Ig titers were determined by
ELISA by using an Ig standard of known concentration. We
recorded a cumulative titer of 1.2 gliter during the 4-day run.
Between days 8 and 9 glucose consumption was at its peak (2
gliter per day), indicating that cells tolerated well the extremely
high cell densities. Production performance was also evaluated
Fig. 4. Class-switched hybridoma cells secrete IgG, retaining antigen bind-
ing. Hybridoma E5 cells (Parent) were treated as described in Materials and
Methods. Hybridoma clones that had class-switched (Switched) were identi-
fied by using an ELISPOT-based screening method. An ELISA measuring spe-
cific binding to human GM-CSF coated onto plates was carried out to assess
binding of either IgM or IgG. Switched IgG mAbs exhibited binding to antigen
comparable to that of the parental IgM.
Fig. 5. Biological activity of human mAbs against GM-CSF. A cell-based assay
was carried out to determine the level of GM-CSF neutralization (% of
inhibition) mediated by G9 and E10 mAbs. Human GM-CSF-dependent TF1
cells were incubated in the presence of 0.1 ngml GM-CSF. No inhibition of
growth was observed when normal isotype control IgG was included in the
reaction, regardless of the concentration used. Both E10 and G9 mAbs neu-
tralized GM-CSF activity.
Fig. 6. Assessment of titers and stability of hybridomas secreting human
mAbs. (A) The hybridoma E5-3D2 line was grown for 60 generations, and then
stability of production was assessed by analyzing frequency of producing cells.
Subclones (X1–X10) derived from 3D2 cells by means of limiting dilution were
randomly chosen, and their Ig production was measured by using an ELISA-
based assay. Absorbance at 405 nm was normalized for colony size by visual
inspection of the cell-containing wells. (B) 3D2 cells were inoculated in a
stirred bioreactor containing 1 liter of serum-free medium, and Ig production
and number of viable cells were recorded on days 1–5. The specific productivity
measured during the log phase was 24 pg per cell per day.
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in a 1-liter-scale fed-batch run by using a stirred bioreactor
system. Cells from a frozen ampule were first thawed and
inoculated in a shake flask and later seeded in stirred bioreactor
(Bauer) containing 1 liter of serum-free medium. Fermentation
was carried out until cell viability dropped below 60% (day 6).
Ig production and cell densities were recorded between days 1
and 5 and are shown in Fig. 6B. During the log phase (days 1–4)
we measured a specific productivity of 24 pg per cell per day with
a doubling time averaging 23.4 h, suggesting good scalability of
these cells from flask to bioreactor while maintaining higher
titers.
Genetic Optimization of Hybridoma-Secreting Human mAbs by Means
ofMismatch Repair (MMR) Regulation.Wepreviously demonstrated
the usefulness of improving the quality of mAb-producing cell
lines using a process, termed morphogenics, that entails the
transient regulation of MMR (17, 18). After increasing the
genetic diversity of the cell pool using this method, high-
throughput screenings are typically carried out to identify sub-
clones exhibiting higher titer, affinity (6, 19), or enhanced growth
rates (L.G., unpublished observation). E5 cells were subjected to
morphogenics to demonstrate the ability to increase phenotypic
diversity in the mAb-secreting lines generated by using our
hybridoma strategy. MMR inhibition was monitored by detect-
ing microsatellite instability in the BAT polyA repeat marker. Of
the 24 BAT alleles analyzed in cells exposed to the morphogenics
process, 3 alleles showed alterations that included single-
nucleotide deletions (shown in Fig. 7A) and insertions. No
microsatellite instability was detected in any of the 24 BAT
alleles in parental cells. Subsequently, parental or morphogen-
ics-treated cells were seeded by limiting dilutions in microplates.
Cell clones were allowed to secret mAbs for 1 week, and their
conditioned medium was analyzed for Ig concentrations by
ELISA. The frequency of clones with OD 1 (high Ig secretion)
was determined from the total number of clones screened (3,763
for parental and 2,437 for morphogenics pool) and found to have
increased by 260% (P  0.0014) in the morphogenics-treated
population (Fig. 7B). We are currently using this process to
enhance growth properties and titers of other hybridoma lines
for preclinical development.
Discussion
Here we present a viable strategy for developing human mAbs
for immunotherapies using an optimized ex vivo immunization
and human B cell immortalization process combined with the
morphogenics process. Specific human mAbs could be obtained
as well by immortalization of B cells from donors exhibiting high
serum reactivity to target antigen. With this approach we are
able to generate highly specific and biologically active mAbs
secreted by stable hybridoma lines. During the preparation of
this article we generated specific fully human mAbs against
Staphylococcus enterotoxin B (unpublished observations), which
could potentially be used for anti-bioterrorism strategies. To
date, we have succeeded in generating specific human mAbs for
all of the antigens targeted. When using human B cells for
developing therapeutic mAbs against self-antigens employing a
hybridoma-based method, some challenges may arise. First,
immune tolerance could prevent identification of human B cells
producing mAbs against self-antigens. This has not been our
experience or that of other investigators, who have also reported
the identification of mAbs derived from peripheral blood mono-
nuclear cells (PBMCs) of normal donors reacting against self-
antigens (20, 21). Second, one can predict that, because of lack
of sufficient maturation outside of the germinal centers, the
binding affinities of mAbs derived by means of ex vivo immu-
nization of human B cells is less vigorous than those of mAbs
obtained through in vivo immunizations. In our ex vivo immu-
nizations, the B cells were derived from healthy volunteers who
exhibited no measurable serum immunoreactivity to target
antigen (titers  1:100; data not shown); however, after antigen
stimulation and B cell immortalization we were able to derive
stable hybridomas secreting high-affinity mAbs specific to the
target antigen. Additional affinity enhancement could poten-
tially be achieved by means of morphogenics, as we previously
reported (6, 19). Third, human B cells used for the generation of
mAbs designed for administration to humans may represent a
potential vehicle of viral transmission. As a standard operating
procedure, we typically prescreen fusion partner cells and
PBMCs from healthy donors to confirm absence of viral DNA
by PCR, including immunodeficiency 1 and 2, hepatitis B and C,
cytomegalovirus, herpesvirus 6, and Epstein–Barr virus (data
not shown). As expected, the hybridoma lines we developed to
date are negative for this panel of viruses, suggesting that our
method does not pose safety risks related to viral transmission
more than conventional methods. Last, transfectoma lines are
often chosen over hybridoma lines because of their generally
better production titers and stability profiles. In our experience,
we were able to obtain stable mAb production for60 doublings
and produce 1 g of mAb per liter during a 4-day hollow-fiber
fermentation run, suggesting that hybridoma cells generated by
using our method are suited for perfusion systems and poten-
tially large-scale manufacturing. Moreover, hybridomas gener-
ated by this process have performed well in fed-batch bioreactor
runs, suggesting a potential use of these lines for commercial
applications. Here we also show that morphogenics can increase
phenotypic diversity of hybridoma lines obtained by using our
method, whereas previously we used this process to stably (50
doublings) increase severalfold titers of human Abs secreted by
hybridoma lines obtained by other methods (L.G., unpublished
observation). In summary, the platform process presented here
offers an alternative approach for a rapid and cost-effective
development of good-quality, fully human Abs for immunother-
apeutic use.
Materials and Methods
Human B Cells, ex Vivo Immunization, and Cell Culturing. In all
procedures followed, cells were grown in 5% CO2 at 37°C.
Leukopacks were obtained from tetanus toxoid-vaccinated
healthy individuals. PBMCs were purified by Ficoll-Paque (Am-
ersham Pharmacia Biosciences), and CD19-positive B cells and
CD4-positive T cells were isolated from PBMCs by an EasySep
human CD4 and CD19 selection kit (StemCell Technologies),
respectively, and mixed to make a B cellT cell pool (BT4 cells).
Fig. 7. Genetic optimization of hybridoma-secreting human mAbs by MMR
regulation. (A) Example of a single-nucleotide deletion in the BAT marker
found in E5 hybridoma cells treated with morphogenics. Dotted lines crossing
the central peak in the histogram represent the size of wild-type (wt) or
contracted (1 nt) fragment. (B) Parental and morphogenics-treated cells
were seeded in microplates to yield 3,763 and 2,437 Ig-secreting clones (OD
0.2), respectively. Ig concentrations were determined by ELISA, and the fre-
quency of clones with OD values 1 was recorded and is expressed as per-
centage of total number of clones screened.
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BT4 cells were cultured in complete RPMI medium 1640
(Invitrogen), which contained 10% heat-inactivated human se-
rum AB (Nabi), 2 mM L-glutamine, 0.1 mM nonessential amino
acids, 1 mM sodium pyruvate, and 55 M 2-mercaptoethanol
(Invitrogen).
For ex vivo immunizations, BT4 cells were cocultured in the
presence of T and B cell epitopes. Briefly, BT4 cells were seeded
at a density of 106 per ml in complete RPMI medium 1640
containing 1 unit per ml tetanus toxoid (Cylex) in the presence
of irradiated autologous PBMCs at a 1:1 ratio to produce
activated T cells (T pool). To generate antigen-activated B cells
(B pool), BT4 cells were seeded at a density of 3  106 cells per
ml in complete RPMI medium 1640 containing 10% human
serum AB, 5% of condition medium from activated T cells, 20
unitsml IL-2, 0.5 ngml IL-6, 100 unitsml IL-10 (PeproTech),
and 250 ngml of a mixture of peptides (Bio-World) representing
various regions of the targeted antigen, synthesized to contain
both T and B cell epitopes as described in ref. 5.
The selected B cell epitopes for GM-CSF were EHVNAIQ-
EARRLLNL, STQPWEHVNAIQEAR, and MASHYKQHC-
PPTPET. The selected B cell epitopes for mesothelin were
EVEKTACPSGKKARE, NKGHEMSPQVATLID, RFVKG-
RGQLDKDTLD, HVEGLKAEERHRPVR, AVRPQDLDT-
CDPRQLD, and SFLGGAPTEDLKALSQ.
T and B pools were separately cultured for 7 days and then
cocultured (106 cells per ml) at a 1:10 ratio, respectively, on a
monolayer of irradiated CHO feeder cells in complete RPMI
medium 1640 containing 10% heat-inactivated human AB se-
rum and 400 unitsml IL-4 (PeproTech). After 5 days, cocul-
tured T and B pools were fused to generate hybridomas as
described.
For the immortalization of pulmonary alveolar proteinosis
patients’ B cells, 100 ml of whole blood was processed to purify
PBMCs. Lymphocytes were cultured for 7–10 days in complete
RPMImedium 1640 containing 10% heat-inactivated FBS (JRH
Biosciences), 2 ngml IL-4 (PeproTech), 2 mM L-glutamine, 0.1
mM nonessential amino acids, 1 mM sodium pyruvate, 55 M
2-mercaptoethanol (Invitrogen), 50 gml transferrin, 5 ngml
phorbol myristate acetate, and 0.5 gml cyclosporine A
(Sigma) in the presence of irradiated CHO feeder cells. Lym-
phocytes were then electrofused as described.
Cell Fusion and ELISA Screening of Antigen-Reacting Hybridomas.
Lymphocytes were fused with K6H6B5 cells (American Type
Culture Collection) by using the Cyto Pulse CEEF-50 apparatus
(Cyto Pulse Sciences) at a 1:1 lymphocytes:K6H6B5 ratio.
Settings were as follows: the first cycle consisted of alignment (40
V, 15 seconds) and pulse (5 V, 0.1 milliseconds); the second cycle
consisted of alignment (75 V, 15 seconds), pulse (800 V, 0.04
milliseconds), and postpulse (60 V, 30 seconds). Fused cells from
each immunization experiment were seeded in 20 flat-bottom
96-well microplates at 5,000 cells per well in complete RPMI
medium 1640 containing 10% heat-inactivated FBS, 2 mM
L-glutamine, 0.1 mM nonessential amino acids, 1 mM sodium
pyruvate, 55 M 2-mercaptoethanol (Invitrogen), 100 M hy-
poxanthine, 0.4 M aminopterin, and 16 M thymidine (HAT;
Sigma). Medium was replaced weekly, and HAT selection was
maintained until completion of antigen reactivity screening (3–5
weeks). On average, 60% of seeded wells contained viable
hybridoma cells, and 1,200 clones were screened after each
immunization. For the identification of antigen-reacting mAbs,
ELISA-based screenings were performed robotically by using a
Biomek FX liquid handling system (Beckman) integrated with
plate washer and spectrophotometer. Briefly, microtiter plates
were coated at room temperature for 6 h with 50 l per well of
in-house produced recombinant antigens (1 gml GM-CSF or
200 ngml mesothelin) diluted in coating buffer (50 mM car-
bonate-bicarbonate, pH 9.4). Plates were then blocked with
binding buffer [PBS containing 1% BSA (Sigma) and 0.05%
Tween 20 (Bio-Rad)] for 2 h at room temperature. Plates were
washed once with washing buffer (PBS containing 0.05% Tween
20), and 50 l of hybridoma supernatant per well was transferred
into the ELISA plates. Binding reaction was carried out at room
temperature for 2 h. Subsequently, plates were washed four
times, and 100 l of horseradish peroxidase-conjugated goat
anti-human IgGM (Jackson ImmunoResearch) diluted
1:10,000 in binding buffer was added, and reactions were carried
out at room temperature for 1.5 h. Finally, plates were washed
four times, and 100 l of SureBlue substrate (Kirkegaard &
Perry Laboratories) per well was added for 10 min. Reactions
were stopped by adding 50 l of 1 N sulfuric acid per well, and
the absorbance was determined at 450 nm. An average of 1.5%
of screened clones typically reacted to the target antigen as
determined by ELISA by using tetanus toxoid as an unrelated
antigen.
FACS Analyses. Ig binding and cell washing steps were conducted
by using ice-cold binding buffer (DPBS without calcium or
magnesium0.5% BSA), reactions were set up in V-bottom
microplates, and samples were analyzed by using a FACSAria
apparatus (BD Biosciences). For the FACS experiment shown in
Fig. 3A, 106 murine anti-GM-CSF hybridoma cells (Mul192,
obtained from Ludwig Institute for Cancer Research) were
loaded with 100 ng of GM-CSF per reaction and then incubated
with anti-GM-CSF human mAb E5. The binding of GM-CSF-
specific mAbs were detected with 10 gml FITC-labeled goat
anti-human Ig (Southern Biotechnology Associates). For the
FACS experiment shown in Fig. 3B, the E10 hybridoma cells
were washed and seeded at 500,000 cells per well in a volume of
90 l. Ten microliters of PE-labeled GM-CSF (R & D Systems)
was then added in each well, and cells were incubated on ice for
1 h. For unlabeled GM-CSF competition, the hybridoma cells
were preincubated with 5 gml recombinant human GM-CSF
(PeproTech) at room temperature for 1 h, washed three times,
and then incubated with PE-GM-CSF as above before analysis.
For the FACS experiment shown in Fig. 4, A431 and A431-K5
cells (a kind gift of Ira Pastan, National Cancer Institute,
Bethesda) were stained with 10 gml C12 mAb or normal
human IgM (Jackson ImmunoResearch) diluted in binding
buffer, and reactions were carried out as above.
GM-CSF Neutralization Bioassay. The GM-CSF-dependent human
erythroleukemia cell line TF1 (American Type Culture Col-
lection) was grown in complete RPMI medium 1640 (see
above) containing 10 ngml recombinant human GM-CSF
(PeproTech). On the day preceding the experiment, TF1 cells
were grown in 0.1% BSA in the absence of GM-CSF. Starved
cells were washed twice, resuspended in assay medium, and
seeded in 96-well microplates at a concentration of 10,000 cells
per well. Wells contained assay medium, 100 pgml GM-CSF,
or GM-CSF preincubated for 1 h with test or isotype control
Ig at concentrations indicated in the figure legends. After 3
days, 40 l of Cell Titer reagent (Promega) was added to each
well, and plates were further incubated at 37°C for 1 h. OD was
measured at 490 nm in a spectrophotometer, and medium
background was subtracted to all samples. Percentage of
GM-CSF neutralization was calculated as follows: 100  (OD
with IgOD without Ig  100).
Ab Class Switch.Hybridoma cells were washed once with 10 ml of
PBS, resuspended in complete RPMI medium 1640, seeded into
flat-bottom 96-well microplates, and incubated at 37°C in 5%
CO2. After 4 days, cells were resuspended by pipetting, and 100
l was transferred to 20 ELISPOT plates (Millipore) coated with
2.3 gml goat anti-human IgG (HL) (Jackson Immuno-
Research). The remaining cells in the tissue plates were fed with
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an additional 100 l of complete RPMI medium 1640. After
overnight incubation, ELISPOT plates were washed three times
with PBS containing 0.05% Tween (PBST), then 100 l of 2
gml goat anti-human IgG (HL)-horseradish peroxidase was
added, and the plates were incubated for 1 h at room temper-
ature with shaking. Plates were washed three times with PBST,
and then 100 l of 3-amino-9-ethylcarbazole substrate solution
(Sigma) was added to wells and incubated for 90 min at room
temperature with shaking. Substrate was aspirated, and plates
were washed with dH2O and allowed to air dry. Clones from
wells exhibiting positive spots (indicating IgG production) were
expanded. The above step was sequentially repeated by reseed-
ing positive clones at 1,000, 100, 10, and 0.25 cells per well while
tracking positive wells and until a single-cell colony was identi-
fied that secreted IgG.
Fermentation Using Hollow Fibers and Stirred Bioreactor. Cells were
seeded at 2.5  105 per ml in a 2-liter bioreactor (B. Braun
Biostat B-DCU) containing 1 liter of HyQCDM4NS0 serum-
free medium (HyClone) maintaining glucose and glutamine at 6
gliter and 4 mM, respectively. Controlled set points were pH
7.1, dO2 40% saturation with air, temperature 37°C, and agita-
tion rates at 80 rpm. Two milliliters of sample was harvested
daily, 1 ml for cell counting by using a Cedex apparatus and 1 ml
used to measure Ig concentrations by ELISA. For the hollow-
fiber run, 108 viable cells were seeded in a FiberCell system
(Bellco) containing 15 ml of complete RPMI medium 1640 and
refed by using an inline reservoir containing 1 liter of fresh
medium when 50% of the glucose was consumed.
MMR Inhibition (Morphogenics) to Increase Genetic Diversity of
Hybridoma Lines.Hybridoma cells were grown in complete RPMI
medium 1640 (negative control) or complete RPMI medium
1640 containing 250 M or 500 MMMR-inhibiting compound
morphocene. Cells were passed at a 1:5 dilution every 3 to 4 days
in fresh media with or without morphocene, and after 3 weeks
cells were harvested and resuspended at 2  106 cells per ml in
FACS buffer (PBS with 1% BSA). Cells were stained with 10
gml FITC-conjugated goat anti-human Ig (Jackson Immu-
noResearch) for 30 min on ice. Cells were washed with 10 ml of
ice-cold FACS buffer and resuspended in 3 ml of FACS buffer.
Ten microliters of Viaprobe (Becton Dickinson) was added for
5 min on ice, and viable cells were sorted for high Ig surface
staining on a FACSAria cell sorter (Becton Dickinson). The gate
was set to sort cells representing the 5% subpopulation with the
highest Ig surface staining. For selection of clones with enhanced
titers, FACS-sorted cells were seeded in U-bottom 96-well plates
and incubated for 1 week at 37°C in 5% CO2. Fifty microliters
of supernatants was harvested from wells and analyzed for IgM
production with ELISA by using goat anti-human IgMG-
coated plates. As an internal control, three wells of each ELISA
plate were seeded with 50 l of 10 ngml human IgM (Jackson
ImmunoResearch). OD values obtained at 450 nm were nor-
malized to the mean values of internal control wells. Wells
exhibiting high IgM signals were expanded for further analysis.
For microsatellite instability analysis, DNA was extracted from
parental or morphocene-treated cells by using the DNeasy
Tissue kit (Qiagen). The BAT poly(A) repeat marker (22) was
amplified by using the D4 fluorescent-labeled BAT-26-F (5-
tcaccatccattgcacagtt-3) and BAT-26-R (5-ctgcgagaaggtact-
caccc-3) primers, pfuUltrahigh-fidelity polymerase (Strat-
agene), and reactions incubated as follows: 5 min at 95°C; 9
cycles of 1 min at 94°C, 1 min at 60°C, and 2 min at 72°C, with
the annealing temperature decreasing by 1°C each cycle; 30
cycles of 1 min at 94°C, 1 min at 52°C, and 2 min at 72°C; final
extension of 10min at 72°C. Single copy of themarker allele were
obtained by using a dilution of DNA the yielded a PCR product
in only 50% of the PCRs. PCR products were diluted 1:10 with
CEQ sample load solution and then loaded into the Beckman
CEQ 8000 Genetic Analysis System for fragment analysis.
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